TITLE

First drug to treat fibromyalgia receives go-ahead

PUB. DATE
July 2007
SOURCE
Drug Topics;7/9/2007, Vol. 151 Issue 13, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article provides information regarding the first drug to treat fibromyalgia. The application of Pregabalin from Pfizer to use the drug for the treatment of fibromyalgia was approved by the U.S. Food & Drug Administration. The result of the two double-blind clinical trials involving approximately 1,800 patients shows that the drug decreased pain, a common complaint associated with the disorder. Pfizer said that the exact mechanism by which Pregabalin works to achieve this effect is undetermined.
ACCESSION #
25886309

 

Related Articles

  • Milnacipran HCl Tablets (Savellaâ„¢). Elliott, William T.; Chan, James // Internal Medicine Alert;2/28/2009, Vol. 31 Issue 4, p30 

    The article reports that the U.S. Food and Drug Administration has approved the uptake of Milnacipran for the management of fibromyalgia.

  • Patients May Benefit From New Fibromyalgia Drug.  // RN;Aug2007, Vol. 70 Issue 8, p28 

    The article reports that the U.S. Food and Drug Administration has approved pregabalin (Lyrica), a drug for the treatment of fibromyalgia. The drug is designed to treat partial seizures and pain associated with diabetic neuropathy. Fibromyalgia affects young or middle-aged women. The side...

  • The Latest Drugs for Fibromyalgia. Mann, Denise Lynn // Arthritis Today;Mar/Apr2009, Vol. 23 Issue 2, p54 

    The article offers information on the two new drugs developed to treat fibromyalgia. It mentions that the two new drugs, namely milnacipran and duloxetine, work through boosting the action of two neurotransmitters which are important factors in the transmission of pain signals. It adds that the...

  • Savella.  // Pharmaceutical Representative;May2009, Vol. 39 Issue 5, p11 

    The article reports on the approval of the Food and Drug Administration (FDA) for Savella of Forest Laboratories Inc. and Cypress Bioscience Inc. in the U.S. The FDA has approved the selective serotonin and norepinephrine dual reuptake inhibitor for the treatment of patients with fibromyalgia....

  • Tonix Pharmaceuticals Reports That Sublingual Formulation of Fibromyalgia Drug Reduces Production of a Psychoactive Metabolite, Improving Suitability for Long- Term, Chronic Treatment.  // Biomedical Market Newsletter;8/15/2012, Vol. 21, p1 

    In this article, Tonix Pharmaceuticals Holding Corp. reports that its new sublingual formulation of its fibromyalgia (FM) drug TNX-102 reduces the production of a problematic metabolite, as per the results from a clinical trial. It informs that TNX-102 is the low dose form of cyclobenzaprine...

  • LE BUPROPION DANS LE TRAITEMENT DE LA FIBROMYALGIE : A PROPOS D'UN CAS. Pitchot, William; Piette, Catherine // Acta Psychiatrica Belgica;2011, Vol. 111 Issue 4, p5 

    FIBROMYALGIA IS A CHRONIC PAIN SYNDROME CHARACTERIZED BY THE PRESENCE OF WIDESPREAD PAIN IN ALL 4 QUADRANTS OF THE BODY FOR AT LEAST 3 MONTHS AND PAIN ON DIGITAL PALPATION IN AT LEAST 11 OF 18 CHARACTERISTIC TENDER POINT SITES. CURRENTLY, TWO ANTIDEPRESSANTS (DULOXETINE AND MILNACIPRAN) ARE...

  • FDA APPROVES DULOXETINE HCI FOR THE MANAGEMENT OF FIBROMYALGIA.  // CNS Spectrums: The International Journal of Neuropsychiatric Med;Jul2008, Vol. 13 Issue 7, p552 

    The article reports that the Food and Drug Administration has approved duloxetine HCI for the management of fibromyalgia in the U.S. The approval was based on the results of two clinical trials representing 874 patients with fibromyalgia. According to the Brief Pain Inventory (BPI), in both...

  • Molecule of the Month. Lindsley, Craig W. // Current Topics in Medicinal Chemistry;Feb2009, Vol. 9 Issue 2, p225 

    The article reports on the decision of the U.S. Food and Drug Administration to approve Savella selective serotonin and norepinephrine dual reuptake inhibitor from Forest Laboratories and Cypress Bioscience on January 14, 2009 for the management of fibromyalgia syndrome (FMS). The safety and...

  • Warning Regarding Topical Anesthetics. Elliott, William T. // OB/GYN Clinical Alert;Mar2009 Supplement, p1 

    The article offers updates related to the actions of the Food and Drug Administration (FDA) in the U.S. The FDA issued a warning concerning topical anesthetics and the risk of life-threatening side effects. The FDA has approved the Tricyclics as treatment of fibromyalgia. The agency is launching...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics